Texas 2015 - 84th Regular

Texas Senate Bill SB1612 Latest Draft

Bill / Introduced Version Filed 03/13/2015

Download
.pdf .doc .html
                            84R10167 EES-F
 By: Kolkhorst S.B. No. 1612


 A BILL TO BE ENTITLED
 AN ACT
 relating to the reimbursement of prescription drugs under the
 Medicaid managed care and child health plan programs.
 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
 SECTION 1.  Section 533.005(a), Government Code, is amended
 to read as follows:
 (a)  A contract between a managed care organization and the
 commission for the organization to provide health care services to
 recipients must contain:
 (1)  procedures to ensure accountability to the state
 for the provision of health care services, including procedures for
 financial reporting, quality assurance, utilization review, and
 assurance of contract and subcontract compliance;
 (2)  capitation rates that ensure the cost-effective
 provision of quality health care;
 (3)  a requirement that the managed care organization
 provide ready access to a person who assists recipients in
 resolving issues relating to enrollment, plan administration,
 education and training, access to services, and grievance
 procedures;
 (4)  a requirement that the managed care organization
 provide ready access to a person who assists providers in resolving
 issues relating to payment, plan administration, education and
 training, and grievance procedures;
 (5)  a requirement that the managed care organization
 provide information and referral about the availability of
 educational, social, and other community services that could
 benefit a recipient;
 (6)  procedures for recipient outreach and education;
 (7)  a requirement that the managed care organization
 make payment to a physician or provider for health care services
 rendered to a recipient under a managed care plan on any claim for
 payment that is received with documentation reasonably necessary
 for the managed care organization to process the claim:
 (A)  not later than:
 (i)  the 10th day after the date the claim is
 received if the claim relates to services provided by a nursing
 facility, intermediate care facility, or group home;
 (ii)  the 30th day after the date the claim
 is received if the claim relates to the provision of long-term
 services and supports not subject to Subparagraph (i); and
 (iii)  the 45th day after the date the claim
 is received if the claim is not subject to Subparagraph (i) or (ii);
 or
 (B)  within a period, not to exceed 60 days,
 specified by a written agreement between the physician or provider
 and the managed care organization;
 (7-a)  a requirement that the managed care organization
 demonstrate to the commission that the organization pays claims
 described by Subdivision (7)(A)(ii) on average not later than the
 21st day after the date the claim is received by the organization;
 (8)  a requirement that the commission, on the date of a
 recipient's enrollment in a managed care plan issued by the managed
 care organization, inform the organization of the recipient's
 Medicaid certification date;
 (9)  a requirement that the managed care organization
 comply with Section 533.006 as a condition of contract retention
 and renewal;
 (10)  a requirement that the managed care organization
 provide the information required by Section 533.012 and otherwise
 comply and cooperate with the commission's office of inspector
 general and the office of the attorney general;
 (11)  a requirement that the managed care
 organization's usages of out-of-network providers or groups of
 out-of-network providers may not exceed limits for those usages
 relating to total inpatient admissions, total outpatient services,
 and emergency room admissions determined by the commission;
 (12)  if the commission finds that a managed care
 organization has violated Subdivision (11), a requirement that the
 managed care organization reimburse an out-of-network provider for
 health care services at a rate that is equal to the allowable rate
 for those services, as determined under Sections 32.028 and
 32.0281, Human Resources Code;
 (13)  a requirement that, notwithstanding any other
 law, including Sections 843.312 and 1301.052, Insurance Code, the
 organization:
 (A)  use advanced practice registered nurses and
 physician assistants in addition to physicians as primary care
 providers to increase the availability of primary care providers in
 the organization's provider network; and
 (B)  treat advanced practice registered nurses
 and physician assistants in the same manner as primary care
 physicians with regard to:
 (i)  selection and assignment as primary
 care providers;
 (ii)  inclusion as primary care providers in
 the organization's provider network; and
 (iii)  inclusion as primary care providers
 in any provider network directory maintained by the organization;
 (14)  a requirement that the managed care organization
 reimburse a federally qualified health center or rural health
 clinic for health care services provided to a recipient outside of
 regular business hours, including on a weekend day or holiday, at a
 rate that is equal to the allowable rate for those services as
 determined under Section 32.028, Human Resources Code, if the
 recipient does not have a referral from the recipient's primary
 care physician;
 (15)  a requirement that the managed care organization
 develop, implement, and maintain a system for tracking and
 resolving all provider appeals related to claims payment, including
 a process that will require:
 (A)  a tracking mechanism to document the status
 and final disposition of each provider's claims payment appeal;
 (B)  the contracting with physicians who are not
 network providers and who are of the same or related specialty as
 the appealing physician to resolve claims disputes related to
 denial on the basis of medical necessity that remain unresolved
 subsequent to a provider appeal;
 (C)  the determination of the physician resolving
 the dispute to be binding on the managed care organization and
 provider; and
 (D)  the managed care organization to allow a
 provider with a claim that has not been paid before the time
 prescribed by Subdivision (7)(A)(ii) to initiate an appeal of that
 claim;
 (16)  a requirement that a medical director who is
 authorized to make medical necessity determinations is available to
 the region where the managed care organization provides health care
 services;
 (17)  a requirement that the managed care organization
 ensure that a medical director and patient care coordinators and
 provider and recipient support services personnel are located in
 the South Texas service region, if the managed care organization
 provides a managed care plan in that region;
 (18)  a requirement that the managed care organization
 provide special programs and materials for recipients with limited
 English proficiency or low literacy skills;
 (19)  a requirement that the managed care organization
 develop and establish a process for responding to provider appeals
 in the region where the organization provides health care services;
 (20)  a requirement that the managed care organization:
 (A)  develop and submit to the commission, before
 the organization begins to provide health care services to
 recipients, a comprehensive plan that describes how the
 organization's provider network will provide recipients sufficient
 access to:
 (i)  preventive care;
 (ii)  primary care;
 (iii)  specialty care;
 (iv)  after-hours urgent care;
 (v)  chronic care;
 (vi)  long-term services and supports;
 (vii)  nursing services; and
 (viii)  therapy services, including
 services provided in a clinical setting or in a home or
 community-based setting; and
 (B)  regularly, as determined by the commission,
 submit to the commission and make available to the public a report
 containing data on the sufficiency of the organization's provider
 network with regard to providing the care and services described
 under Paragraph (A) and specific data with respect to Paragraphs
 (A)(iii), (vi), (vii), and (viii) on the average length of time
 between:
 (i)  the date a provider makes a referral for
 the care or service and the date the organization approves or denies
 the referral; and
 (ii)  the date the organization approves a
 referral for the care or service and the date the care or service is
 initiated;
 (21)  a requirement that the managed care organization
 demonstrate to the commission, before the organization begins to
 provide health care services to recipients, that:
 (A)  the organization's provider network has the
 capacity to serve the number of recipients expected to enroll in a
 managed care plan offered by the organization;
 (B)  the organization's provider network
 includes:
 (i)  a sufficient number of primary care
 providers;
 (ii)  a sufficient variety of provider
 types;
 (iii)  a sufficient number of providers of
 long-term services and supports and specialty pediatric care
 providers of home and community-based services; and
 (iv)  providers located throughout the
 region where the organization will provide health care services;
 and
 (C)  health care services will be accessible to
 recipients through the organization's provider network to a
 comparable extent that health care services would be available to
 recipients under a fee-for-service or primary care case management
 model of Medicaid managed care;
 (22)  a requirement that the managed care organization
 develop a monitoring program for measuring the quality of the
 health care services provided by the organization's provider
 network that:
 (A)  incorporates the National Committee for
 Quality Assurance's Healthcare Effectiveness Data and Information
 Set (HEDIS) measures;
 (B)  focuses on measuring outcomes; and
 (C)  includes the collection and analysis of
 clinical data relating to prenatal care, preventive care, mental
 health care, and the treatment of acute and chronic health
 conditions and substance abuse;
 (23)  subject to Subsection (a-1), a requirement that
 the managed care organization develop, implement, and maintain an
 outpatient pharmacy benefit plan for its enrolled recipients:
 (A)  that exclusively employs the vendor drug
 program formulary and preserves the state's ability to reduce
 waste, fraud, and abuse under the Medicaid program;
 (B)  that adheres to the applicable preferred drug
 list adopted by the commission under Section 531.072;
 (C)  that includes the prior authorization
 procedures and requirements prescribed by or implemented under
 Sections 531.073(b), (c), and (g) for the vendor drug program;
 (D)  for purposes of which the managed care
 organization:
 (i)  may not negotiate or collect rebates
 associated with pharmacy products on the vendor drug program
 formulary; and
 (ii)  may not receive drug rebate or pricing
 information that is confidential under Section 531.071;
 (E)  that complies with the prohibition under
 Section 531.089;
 (F)  under which the managed care organization may
 not prohibit, limit, or interfere with a recipient's selection of a
 pharmacy or pharmacist of the recipient's choice for the provision
 of pharmaceutical services under the plan through the imposition of
 different copayments;
 (G)  that allows the managed care organization or
 any subcontracted pharmacy benefit manager to contract with a
 pharmacist or pharmacy providers separately for specialty pharmacy
 services, except that:
 (i)  the managed care organization and
 pharmacy benefit manager are prohibited from allowing exclusive
 contracts with a specialty pharmacy owned wholly or partly by the
 pharmacy benefit manager responsible for the administration of the
 pharmacy benefit program; and
 (ii)  the managed care organization and
 pharmacy benefit manager must adopt policies and procedures for
 reclassifying prescription drugs from retail to specialty drugs,
 and those policies and procedures must be consistent with rules
 adopted by the executive commissioner and include notice to network
 pharmacy providers from the managed care organization;
 (H)  under which the managed care organization may
 not prevent a pharmacy or pharmacist from participating as a
 provider if the pharmacy or pharmacist agrees to comply with the
 financial terms and conditions of the contract as well as other
 reasonable administrative and professional terms and conditions of
 the contract;
 (I)  under which the managed care organization may
 include mail-order pharmacies in its networks, but may not require
 enrolled recipients to use those pharmacies, and may not charge an
 enrolled recipient who opts to use this service a fee, including
 postage and handling fees;
 (J)  under which the managed care organization or
 pharmacy benefit manager, as applicable, must pay claims in
 accordance with Section 843.339, Insurance Code; and
 (K)  under which the managed care organization or
 pharmacy benefit manager, as applicable, must comply with Section
 533.00512 as a condition of contract retention and renewal[:
 [(i)     to place a drug on a maximum allowable
 cost list, must ensure that:
 [(a)     the drug is listed as "A" or "B"
 rated in the most recent version of the United States Food and Drug
 Administration's Approved Drug Products with Therapeutic
 Equivalence Evaluations, also known as the Orange Book, has an "NR"
 or "NA" rating or a similar rating by a nationally recognized
 reference; and
 [(b)     the drug is generally available
 for purchase by pharmacies in the state from national or regional
 wholesalers and is not obsolete;
 [(ii)     must provide to a network pharmacy
 provider, at the time a contract is entered into or renewed with the
 network pharmacy provider, the sources used to determine the
 maximum allowable cost pricing for the maximum allowable cost list
 specific to that provider;
 [(iii)     must review and update maximum
 allowable cost price information at least once every seven days to
 reflect any modification of maximum allowable cost pricing;
 [(iv)     must, in formulating the maximum
 allowable cost price for a drug, use only the price of the drug and
 drugs listed as therapeutically equivalent in the most recent
 version of the United States Food and Drug Administration's
 Approved Drug Products with Therapeutic Equivalence Evaluations,
 also known as the Orange Book;
 [(v)     must establish a process for
 eliminating products from the maximum allowable cost list or
 modifying maximum allowable cost prices in a timely manner to
 remain consistent with pricing changes and product availability in
 the marketplace;
 [(vi)  must:
 [(a)     provide a procedure under which a
 network pharmacy provider may challenge a listed maximum allowable
 cost price for a drug;
 [(b)     respond to a challenge not later
 than the 15th day after the date the challenge is made;
 [(c)     if the challenge is successful,
 make an adjustment in the drug price effective on the date the
 challenge is resolved, and make the adjustment applicable to all
 similarly situated network pharmacy providers, as determined by the
 managed care organization or pharmacy benefit manager, as
 appropriate;
 [(d)     if the challenge is denied,
 provide the reason for the denial; and
 [(e)     report to the commission every 90
 days the total number of challenges that were made and denied in the
 preceding 90-day period for each maximum allowable cost list drug
 for which a challenge was denied during the period;
 [(vii)     must notify the commission not later
 than the 21st day after implementing a practice of using a maximum
 allowable cost list for drugs dispensed at retail but not by mail;
 and
 [(viii)     must provide a process for each of
 its network pharmacy providers to readily access the maximum
 allowable cost list specific to that provider];
 (24)  a requirement that the managed care organization
 and any entity with which the managed care organization contracts
 for the performance of services under a managed care plan disclose,
 at no cost, to the commission and, on request, the office of the
 attorney general all discounts, incentives, rebates, fees, free
 goods, bundling arrangements, and other agreements affecting the
 net cost of goods or services provided under the plan; and
 (25)  a requirement that the managed care organization
 not implement significant, nonnegotiated, across-the-board
 provider reimbursement rate reductions unless:
 (A)  subject to Subsection (a-3), the
 organization has the prior approval of the commission to make the
 reduction; or
 (B)  the rate reductions are based on changes to
 the Medicaid fee schedule or cost containment initiatives
 implemented by the commission.
 SECTION 2.  Subchapter A, Chapter 533, Government Code, is
 amended by adding Section 533.00512 to read as follows:
 Sec. 533.00512.  REIMBURSEMENT METHODOLOGY FOR PRESCRIPTION
 DRUGS. (a)  A managed care organization that contracts with the
 commission under this chapter or a pharmacy benefit manager
 administering a pharmacy benefit program on behalf of the managed
 care organization shall reimburse a pharmacy or pharmacist that
 dispenses a prescribed prescription drug to a recipient for:
 (1)  subject to Subsection (b), the drug ingredient
 cost using the National Average Drug Acquisition Cost published by
 the Centers for Medicare and Medicaid Services; and
 (2)  except as provided by Subsection (e), the cost of
 dispensing the drug by paying the pharmacy or pharmacist, as
 applicable, a dispensing fee equal to the greater of $7.93 plus an
 amount equal to 1.96 percent of the amount paid under Subdivision
 (1) or Subsection (b), as applicable.
 (b)  If a National Average Drug Acquisition Cost is not
 available to determine the ingredient cost of a prescription drug
 for the purpose of Subsection (a)(1), the managed care organization
 or pharmacy benefit manager shall reimburse the pharmacy or
 pharmacist for the drug ingredient cost using:
 (1)  the wholesale acquisition cost, less an amount
 equal to two percent of that cost; or
 (2)  an amount equal to the amount paid for the drug
 under the traditional fee-for-service arrangement.
 (c)  A managed care organization that contracts with the
 commission under this chapter or a pharmacy benefit manager
 administering a pharmacy benefit program on behalf of the managed
 care organization shall review and update cost information at least
 once every seven days to reflect any modification of the National
 Average Drug Acquisition Cost or wholesale acquisition cost for a
 prescription drug.
 (d)  Not later than December 1, 2016, the commission shall
 complete a study of the average cost of dispensing prescription
 drugs for pharmacies and pharmacists participating in the Medicaid
 managed care and child health plan programs.  The commission may
 contract with a third party to conduct the study required by this
 subsection.  This subsection expires September 1, 2017.
 (e)  If the executive commissioner finds, as a result of the
 study conducted under Subsection (d), that the average cost of
 dispensing prescription drugs under the Medicaid managed care and
 child health plan programs is greater than $10.12, the executive
 commissioner by rule may establish a dispensing fee greater than
 the fee required by Subsection (a)(2).
 SECTION 3.  Subchapter D, Chapter 62, Health and Safety
 Code, is amended by adding Section 62.160 to read as follows:
 Sec. 62.160.  REIMBURSEMENT METHODOLOGY FOR PRESCRIPTION
 DRUGS. A managed care organization providing pharmacy benefits
 under the child health plan program or a pharmacy benefit manager
 administering a pharmacy benefit program on behalf of the managed
 care organization shall comply with Section 533.00512, Government
 Code.
 SECTION 4.  Section 533.005(a-2), Government Code, is
 repealed.
 SECTION 5.  If before implementing any provision of this Act
 a state agency determines that a waiver or authorization from a
 federal agency is necessary for implementation of that provision,
 the agency affected by the provision shall request the waiver or
 authorization and may delay implementing that provision until the
 waiver or authorization is granted.
 SECTION 6.  This Act takes effect September 1, 2015.